Dear editor,
We read with interest of the report by Hraiech and colleagues [
1] about the
Herpesviridae reactivation among non-immunocompromised critically ill patients with acute respiratory distress syndrome (ARDS) supported with extracorporeal membrane oxygenation (ECMO). They found that
Herpesviridae reactivation is frequent among patients with severe ARDS under ECMO and is associated with a longer duration of mechanical ventilation. From our point of view, a few other concerns related to who, how and why for the
Herpesviridae reactivation affects outcome in ARDS could be raised.
First, who has a
Herpesviridae reactivation should be focused? In Hraiech’s study [
1], they determined the frequency of
Herpesviridae reactivation and its impact on prognosis only in patients during ECMO for severe ARDS. However,
Herpesviridae reactivation occurring in all ARDS patients should be investigated. Within all ARDS patients, by comparing the reactivation related to ARDS with no-ECMO support, and the reactivation after ECMO insertion, whether a
Herpesviridae reactivation was worsening under ECMO could be confirmed.
The second question is how a
Herpesviridae reactivation or active infection should be defined in ARDS patients? In Hraiech’s report [
1], Herpes Simplex Virus (HSV) reactivation was diagnosed mainly by throat or BAL samples, and only 3 patients (5%) exhibited a positive HSV viremia, and cytomegalovirus (CMV) reactivation was diagnosed mainly from blood PCR. However, whether a positive PCR from the airway sample should be treated as a reactivation or as an evidence of infection is still debatable [
2]. Previous study [
3,
4] found that seropositivity for Epstein–Barr virus (EBV), one of
Herpesviridae, was associated with mortality of ICU patients with respiratory failure. Thus, when looking for the association of reactivation and the outcome, we suggested that only patients with a seropositivity for
Herpesviridae should be included. Furthermore, Hraiech and colleagues [
1] found that HSV reactivation occurred earlier than CMV reactivation. In our study, airway sample may show an earlier and higher positivity than serum samples for EBV [
3]. Therefore, the time of reactivation for HSV and CMV should be compared for samples from serum and airway, respectively.
Finally, why
Herpesviridae reactivation caused a poor outcome in ARDS patients with ECMO support is still unclear. On the one hand,
Herpesviridae reactivation may indicate an active infection and related damage to the organ function, which lead to a poor prognosis. However, in Hraiech’s study [
1], the definition of reactivation by a positive airway sample could not interpreted as true infection. And they reported that alveolar procollagen III level, an indicator of pulmonary fibrosis, was not different between both groups. These results could not support that reactivation leads a poor outcome by infection. On the other hand, in our previous report [
3], the seropositivity for EBV associated with mortality maybe correlated with a low CD3+ CD8+ T cell count. Thus, the biomarkers of an ARDS or sepsis-induced immunoparalysis should be explored as a possible mechanism of reactivation and poor outcome [
5].
Overall, whether Herpesviridae reactivation is directly responsible for worse clinical outcomes or if it is a consequence and a witness of the severity of the disease, as in ARDS populations with/without ECMO, still needs further investigation.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by/4.0/.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.